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Female sex workers’ livelihoods in Zimbabwe have
been severely impacted by the coronavirus disease
2019 pandemic due to closure of entertainment
venues. Competition over fewer clients has reduced
ability to negotiate condom use. At the same time
as partner numbers have decreased, frequency of
reported condomless sex has not increased, suggest-
ing potential reduction in overall HIV and sexually
transmitted infection risk and an opportunity for
programmes to reach sex workers with holistic social
and economic support and prevention services.
The global coronavirus disease 2019 (COVID-19)
pandemic has disrupted economies across the world,
disproportionately threatening the livelihoods of people
working in the informal sector with low-wage jobs [1].
These include sex workers, who are further marginalized
due to the criminalization of sex work [2]. Reports from
diverse regions suggest sex workers continue to work
despite restrictions to survive, but struggle to find clients
and experience increased vulnerability to stigma, violence
and police harassment [3].
In Zimbabwe, Sisters with a Voice is a nationally scaled
HIV prevention and treatment programme for sex
workers that reaches over 26 000 female sex workers
(FSW) annually with social and clinical services [4].
During Zimbabwe’s national lockdown (April–October
2020), we collected data from FSW visiting our two
largest clinics in Harare and Bulawayo on their client
numbers, earned income, work conditions and condom-
less sex, which we compared with our most recent
representative data from Respondent Driven Surveys
(RDS) conducted in these sites in 2017.
We found 90% FSW attending these clinics reported
reduced client numbers. In 2017 RDS, weekly client
numbers averaged 14 in Harare and eight in Bulawayo but
since lockdown, FSW reported mean monthly client
numbers of nine and three, respectively. Of these, FSW
reported condomless sex with two of nine clients (Harare)
and one of three (Bulawayo) following lockdown compared
with 2 of 52 and 1 of 32 in 2017, but absolute numbers of
condomless partners did not increase. Anecdotally, sex
workers report that closure of entertainment venues,
restrictions on mobility, and male clients’ fear of contracting
COVID-19 have significantly reduced earnings. When
FSW do procure a client, they are less likely to negotiate
condom use or high fees, and are more willing to accept
condomless sex and exchange sex for food.
Restrictions in Zimbabwe have constrained FSW ability
to work, negotiate condom use or refuse clients,
increasing their social and economic marginalization.
However, it is possible that a reduction in overall client
numbers without an accompanying increase in condom-
less sex has not increased their risk of HIV and STI,
and possibly decreased it. The Sisters programme has
addressed FSW precarious survival at this time by
offering psychosocial support and livelihood assistance;
for example, by facilitating self-help groups to set up
shared savings and income support schemes, including
making facemasks to sell. It is imperative to address FSWs’
needs holistically as well as reinforce HIV prevention
messages to take advantage of a possible reduction in HIV
risk by ensuring its sustainability.
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Safety and antibody response to the first dose of
severe acute respiratory syndrome coronavirus 2
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In this study of 12 people with HIV (PWH) who
received the first dose of SARS-CoV-2 mRNA
vaccination, anti-SARS-CoV-2 receptor-binding
domain antibodies were detectable in all partici-
pants; lower antibody levels were seen in those with
lower CD4R counts, and vaccine reactions were
generally mild.
People with HIV (PWH) were included in the original
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) mRNA vaccine trials in small numbers [0.6% for
mRNA-1273 (Moderna) and 0.5% for BNT162b2
(Pfizer/BioNTech)], yet the immunogenicity and safety
of the vaccines has not been reported in this subgroup
[1,2]. Vaccination is currently recommended for all
PWH; however, some have expressed vaccine hesitancy
for fear of harmful side effects and unknown effectiveness
[3,4]. We, therefore, studied the antibody response and
reactogenicity to the first dose of SARS-CoV-2 mRNA
vaccination in PWH.
PWH in the United States at least 18 years old without
prior known history of coronavirus disease 2019
(COVID-19) infection were recruited to participate in
this prospective cohort via social media outreach to
national HIV/AIDS organizations between 15 January
2021 to 5 March 2021. Participants enrolled via an online
questionnaire and reported their most recent HIV viral
load (detectable/undetectable), most recent CD4þ count
(<200, 200–350, 350–499, 500 cells/ml), presence/
absence of current antiretroviral therapy (ART) and
duration of treatment (<6 or 6 months).
Participants underwent SARS-CoV-2 antibody testing
via the Roche Elecsys anti-SARS-CoV-2S enzyme
immunoassay prior to dose 2. The assay measures total
antibody (IgM, IgG) to the SARS-CoV-2 S-receptor-
binding domain (RBD) protein [5]. Results range from
<0.4 U/ml to >250 U/ml; positive is 0.8 U/ml. The
assay is analogous to those used in early mRNA vaccine
trials, in which, for example, 100% seroreactivity was seen
by 15 days after Moderna mRNA-1273 vaccination [6,7].
One week after receiving the first dose, participants
completed a questionnaire detailing local and systemic
reactions and other adverse events including anaphylaxis,
incident neurologic diagnoses, infections, or SARS-
CoV-2 infection. This study was approved by the Johns
Hopkins Institutional Review Board (IRB00248540);
participants consented electronically.
Twelve participants were studied, completing antibody
testing at a median [interquartile range (IQR)] of 21 (17–
27) days after vaccination (50% Moderna, 50% Pfizer/
BioNTech) (Table 1). Median (IQR) age was 64 years
(57, 70); all were male, 8% were nonwhite. All were on
ARTat least 6 months and 92% had an undetectable HIV
viral load. Six (50%), three (25%), one (8%), and two
(17%) of individuals reported CD4þ counts at least 500,
350–499, 200–349, and less than 200 cells/ml, respec-
tively. Anti-RBD assays were positive for all, ranging from
2.12 U/ml to >250 U/ml.
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Table 1. Demographics, clinical characteristics, and severe acute respiratory syndrome coronavirus 2 anti-receptor-binding domain levels after
a single dose of SARS-CoV-2 mRNA vaccination of 12 people with HIV on antiretroviral therapy.









1 61 Male White 27 Moderna <200 Undetectable 2.1
2 75 Male White 21 Moderna <200 Undetectable 2.5
3 63 Male White 19 Pfizer/BioNTech 350–499 Undetectable 4.6
4 55 Male White 20 Pfizer/BioNTech 350–499 Undetectable 7.7
5 67 Male White 28 Moderna 500 Undetectable 44
6 68 Male Asian 24 Moderna 500 Undetectable 66
7 33 Male White 16 Pfizer/BioNTech 500 Undetectable 85.3
8 72 Male White 27 Moderna 350–499 Undetectable 138
9 56 Male White 27 Moderna 500 Undetectable 148.6
10a 58 Male White 14 Pfizer/BioNTech 500 Detectable 234.6
11 70 Male White 15 Pfizer/BioNTech 200–349 Undetectable >250
12 65 Male White 20 Pfizer/BioNTech 500 Undetectable >250
aViral load of participant 10 was reported as 35 copies/ml; specific viral loads were not measured.
